Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M6223 Monotherapy and in Combination With Bintrafusp Alfa in Solid Tumors
NCT04457778Phase 1Completed
- Sponsor
- EMD Serono
- Start
- Jul 2020
- Primary completion
- Jun 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of dargistotug in solid tumor (2 arms), sponsored by EMD Serono. Primary endpoints: Dose Limiting Toxicities, Treatment-Emergent Adverse Events and 1 more. Started Jul 2020; status: completed.
02
Drugs
dargistotug
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04457778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04457778.